New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - emtricitabine 200mg;  ; tenofovir disoproxil maleate 300mg equivalent to tenofovir disoproxil 245 mg; emtricitabine 200mg; tenofovir disoproxil maleate 300mg equivalent to tenofovir disoproxil 245 mg - film coated tablet - 200 mg/300 mg - active: emtricitabine 200mg   tenofovir disoproxil maleate 300mg equivalent to tenofovir disoproxil 245 mg excipient: colloidal silicon dioxide hyprolose iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose opadry green 31k510010 active: emtricitabine 200mg tenofovir disoproxil maleate 300mg equivalent to tenofovir disoproxil 245 mg excipient: colloidal silicon dioxide hyprolose iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose opadry green 32k510087 - treatment of hiv-1 infection tenofovir disoproxil emtricitabine viatris is indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents.

Kenya - English - Pharmacy and Poisons Board

mylan laboratories limited plot no.564/a/22, road no.92, jubilee hills, - emtricitabine/ tenofovir alafenamide fumarate - film-coated tablet - emtricitabine 200 mg/tenofovir alafenamide… - emtricitabine and tenofovir alafenamide

Kenya - English - Pharmacy and Poisons Board

hetero labs limited 7-2-a2, hetero corporate, industrial estates, - emtricitabine and tenofovir alafenamide - film-coated tablet - emtricitabine and tenofovir alafenamide tablets… - emtricitabine and tenofovir alafenamide

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine 200 mg - truvada® , a combination of emtriva® and viread® , is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 17 kg [see dosage and administration (2) and clinical studies (14)] . the following points should be considered when initiating therapy with truvada for the treatment of hiv-1 infection: - it is not recommended that truvada be used as a component of a triple nucleoside regimen. - truvada should not be coadministered with atripla® , complera® , emtriva, genvoya® , odefsey® , stribild® , viread or lamivudine-containing products [see warnings and precautions (5.4)] . - in treatment experienced patients, the use of truvada should be guided by laboratory testing and treatment history [see microbiology (12.4)] . truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinical trial

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), rilpivirine hydrochloride (unii: 212wax8kdd) (rilpivirine - unii:fi96a8x663), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine 200 mg - complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adult patients with hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy. this indication is based on safety and efficacy analyses through 96 weeks from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz [see clinical studies (14)] . the following points should be considered when initiating therapy with complera: - more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure (hiv-1 rna ≥50 copies/ml) compared to rilpivirine-treated subjects with hiv-1 rna less than or equal to 100,000 copies/ml [see clinical studies (14)] . - regardless of hiv-1 rna level at the start of therapy, more rilpivirine-treated subjects with cd4+ cell count less than 200 cells/mm3 exper

United States - English - NLM (National Library of Medicine)

a-s medication solutions - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), rilpivirine hydrochloride (unii: 212wax8kdd) (rilpivirine - unii:fi96a8x663), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine 200 mg - complera® , a combination of two nucleoside analog hiv-1 reverse transcriptase inhibitors (nrtis) (emtricitabine and tenofovir disoproxil fumarate) and one non-nucleoside reverse transcriptase inhibitor (nnrti) (rilpivirine), is indicated for use as a complete regimen for the treatment of hiv-1 infection in patients 12 years of age and older with no antiretroviral treatment history and with hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy, and in certain virologically-suppressed (hiv-1 rna <50 copies/ml) patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see below). - the following points should be considered when initiating therapy with complera in patients with no antiretroviral treatment history:   more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure (hiv-1 rna ≥50 copies/ml) compared

United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir - unii:99yxe507il) - emtricitabine 200 mg - truvada® , a combination of emtriva® and viread® , is indicated in combination with other antiretroviral agents (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older. the following points should be considered when initiating therapy with truvada for the treatment of hiv-1 infection: - it is not recommended that truvada be used as a component of a triple nucleoside regimen. - truvada should not be coadministered with atripla® , emtriva, viread or lamivudine-containing products [see warnings and precautions (5.4)] . - in treatment experienced patients, the use of truvada should be guided by laboratory testing and treatment history [see clinical pharmacology (12.4)] . none. pregnancy category b emtricitabine: the incidence of fetal variations and malformations was not increased in embryofetal toxicity studies performed with emtricitabine in mice at exposures (auc) approximately 60-fold hi

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir - unii:99yxe507il) - emtricitabine 200 mg - truvada® , a combination of emtriva® and viread® , is indicated in combination with other antiretroviral agents (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of hiv-1 infection in adults. the following points should be considered when initiating therapy with truvada for the treatment of hiv-1 infection: - it is not recommended that truvada be used as a component of a triple nucleoside regimen. - truvada should not be coadministered with atripla® , emtriva, viread or lamivudine-containing products [see warnings and precautions (5.4)] . - in treatment experienced patients, the use of truvada should be guided by laboratory testing and treatment history [see clinical pharmacology (12.4)] . none. pregnancy category b emtricitabine: the incidence of fetal variations and malformations was not increased in embryofetal toxicity studies performed with emtricitabine in mice at exposures (auc) approximately 60-fold higher and in rabbits at approximately 120-fold hig

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine 200 mg - truvada® , a combination of emtriva® and viread® , is indicated in combination with other antiretroviral agents (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older. the following points should be considered when initiating therapy with truvada for the treatment of hiv-1 infection: - it is not recommended that truvada be used as a component of a triple nucleoside regimen. - truvada should not be coadministered with atripla® , complera® , emtriva, viread or lamivudine-containing products [see warnings and precautions (5.4)] . - in treatment experienced patients, the use of truvada should be guided by laboratory testing and treatment history [see microbiology (12.4)] . truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinical trials in men who h

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine 200 mg - truvada® , a combination of emtriva® and viread® , is indicated in combination with other antiretroviral agents (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older. the following points should be considered when initiating therapy with truvada for the treatment of hiv-1 infection: - it is not recommended that truvada be used as a component of a triple nucleoside regimen. - truvada should not be coadministered with atripla® , complera® , emtriva, stribild® , viread or lamivudine-containing products [see warnings and precautions (5.4)] . - in treatment experienced patients, the use of truvada should be guided by laboratory testing and treatment history [see clinical pharmacology (12.4)] . truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinic